Demirkan, B. Et Al. 2006. The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.1 , 9-14.

Demirkan, B., Ozcan, M., Alacacioglu, A., Yuksel, F., Undar, B., & Alakavuklar, M., (2006). The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.1, 9-14.

Demirkan, HATİCE Et Al. "The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer," CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.1, 9-14, 2006

Demirkan, HATİCE M. Et Al. "The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer." CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.1, pp.9-14, 2006

Demirkan, B. Et Al. (2006) . "The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer." CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.12, no.1, pp.9-14.

@article{article, author={HATİCE MİRAÇ BİNNAZ DEMİRKAN Et Al. }, title={The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer}, journal={CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS}, year=2006, pages={9-14} }